CSIMarket Company Name, Ticker, Suppliers, else..
 
Tiziana Life Sciences Ltd  (TLSA)
Other Ticker:  
 
 
Price: $1.1100 $-0.18 -13.953%
Day's High: $1.2899 Week Perf: -28.39 %
Day's Low: $ 1.04 30 Day Perf: 23.33 %
Volume (M): 1,111 52 Wk High: $ 1.91
Volume (M$): $ 1,234 52 Wk Avg: $0.90
Open: $1.25 52 Wk Low: $0.41



 Market Capitalization (Millions $) 116
 Shares Outstanding (Millions) 104
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 0

Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a biotechnology company that focuses on the development and commercialization of innovative therapies for diseases with high unmet medical need. The company is headquartered in London, United Kingdom, with operations in the United States and Italy. Tiziana Life Sciences primarily focuses on developing treatments for cancer, autoimmune and inflammatory diseases, and COVID-19. The company's pipeline includes potential therapies based on monoclonal antibodies and small molecules to target specific disease mechanisms. Tiziana Life Sciences aims to provide patients with safe and effective treatments that can improve their quality of life.


   Company Address: Clarendon House Hamilton HM 11
   Company Phone Number: 20 7495 2379   Stock Exchange / Ticker: TLSA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.19%    
AZN   -3.15%    
JNJ   -0.58%    
NVS   -0.08%    
PFE   -0.65%    
SNY   -3.43%    
• View Complete Report
   



Partnership

Tiziana Life Sciences Pioneering a Nasal Revolution in Immunomodulation

Published Fri, Feb 21 2025 5:36 PM UTC

In a strategic move that underscores its commitment to innovation in the biopharmaceutical sector, Tiziana Life Sciences has announced a collaborative agreement with Renaissance Lakewood, LLC, a notable player in Contract Development and Manufacturing Organizations (CDMO) specializing in nasal drug delivery. This partnership, revealed on February 21, 2025, centers around the...
Stock Market Announcement

Tiziana Life Sciences Charts a Fearless Course in Biotech with Innovative Intranasal Therapy and Strategic Financial Resilience,

Published Thu, Jan 23 2025 1:54 PM UTC

Tiziana Life Sciences Signals Positive Forward Trajectory with Strategic Capital Decision in Immunotherapy DevelopmentOn January 23, 2025, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a notable contender in the biotechnology sector, issued a press release highlighting its decision to abstain from capital-raising activities in the near future. This announcement has significant...
Product Service News

Tiziana Life Sciences Secures ALS Association Grant for Innovative Therapy Trial Amid Competitive Financial Landsca...

Published Tue, Nov 19 2024 12:00 PM UTC

New York, Nov. 19, 2024 Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company focused on developing transformative immunomodulation therapies, announced a significant milestone in their journey towards combating Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig s disease. The ALS Association has approved Tiziana?s grant application...
Clinical Study

NIH Awards $4 Million Grant to Investigate Intranasal Anti-CD3 Monoclonal Antibody for Alzheimers Disease

Published Thu, Sep 19 2024 11:00 AM UTC

On September 19, 2024, Tiziana Life Sciences, a biotechnology firm specializing in immunomodulation therapies, announced the receipt of a significant $4 million grant from the National Institutes of Health (NIH) to study a promising therapeutic approach for Alzheimer s disease (AD). This grant, awarded by the NIH s National Institute on Aging, will be led by Dr. Howard Wein...
Management Announcement

Tiziana Life Sciences: An Innovative Breakthrough Paves the Way, but Financial Challenges Persist

Published Wed, Jul 24 2024 11:00 AM UTC

Tiziana Life Sciences: Innovative Breakthrough and Ongoing Financial Challenges Shape Its Future
In an exciting breakthrough, Tiziana Life Sciences, a renowned biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its intranasal formulation of foralumab. This formulation, a fully human anti-CD3 monoclonal antibo...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com